Toward gene therapy of hypertension: Experimental study on hypertensive ISIAH rats
- Authors: Repkova M.N.1,2, Levina A.S.1,2, Seryapina A.A.1,3, Shikina N.V.1,4, Bessudnova E.V.1,4, Zarytova V.F.1,2, Markel A.L.1,3
-
Affiliations:
- Novosibirsk State University
- Institute of Chemical Biology and Fundamental Medicine
- Institute of Cytology and Genetics
- Institute of Catalysis
- Issue: Vol 82, No 4 (2017)
- Pages: 454-457
- Section: Article
- URL: https://journals.rcsi.science/0006-2979/article/view/151336
- DOI: https://doi.org/10.1134/S000629791704006X
- ID: 151336
Cite item
Abstract
TiO2-based nanocomposites were prepared to deliver oligonucleotides into cells. The nanocomposites were designed by the immobilization of polylysine-containing oligonucleotides on TiO2-nanoparticles (TiO2·PL-DNA). We showed for the first time the possibility of using the proposed nanocomposites for treatment of hypertensive disease by introducing them into hypertensive ISIAH rats developed as a model of stress-sensitive arterial hypertension. The mRNA of the gene encoding angiotensin I-converting enzyme (ACE1) involved in the synthesis of angiotensin II was chosen as a target. Administration (intraperitoneal injection and inhalation) of the nanocomposite showed a significant (by 20-30 mm Hg) decrease in systolic blood pressure when the nanocomposite contained the ACE1 gene-targeted oligonucleotide. When using the oligonucleotide with a random sequence, no effect was observed. Further development and improvement of the inhalation nanocomposite drug delivery to systemic hypertensive disease treatment promises new possibilities for clinical practice.
About the authors
M. N. Repkova
Novosibirsk State University; Institute of Chemical Biology and Fundamental Medicine
Email: markel@bionet.nsc.ru
Russian Federation, Novosibirsk, 630090; Novosibirsk, 630090
A. S. Levina
Novosibirsk State University; Institute of Chemical Biology and Fundamental Medicine
Email: markel@bionet.nsc.ru
Russian Federation, Novosibirsk, 630090; Novosibirsk, 630090
A. A. Seryapina
Novosibirsk State University; Institute of Cytology and Genetics
Email: markel@bionet.nsc.ru
Russian Federation, Novosibirsk, 630090; Novosibirsk, 630090
N. V. Shikina
Novosibirsk State University; Institute of Catalysis
Email: markel@bionet.nsc.ru
Russian Federation, Novosibirsk, 630090; Novosibirsk, 630090
E. V. Bessudnova
Novosibirsk State University; Institute of Catalysis
Email: markel@bionet.nsc.ru
Russian Federation, Novosibirsk, 630090; Novosibirsk, 630090
V. F. Zarytova
Novosibirsk State University; Institute of Chemical Biology and Fundamental Medicine
Email: markel@bionet.nsc.ru
Russian Federation, Novosibirsk, 630090; Novosibirsk, 630090
A. L. Markel
Novosibirsk State University; Institute of Cytology and Genetics
Author for correspondence.
Email: markel@bionet.nsc.ru
Russian Federation, Novosibirsk, 630090; Novosibirsk, 630090
![](/img/style/loading.gif)